Navigation Links
New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C)

ion can significantly interfere with daily activities and reduce patients' quality of life, resulting in absences from school, missed work and reduced productivity.

Three main types include IBS with constipation (IBS-C), with diarrhea (IBS-D) and with mixed symptoms of constipation and diarrhea (IBS-M). In IBS- C, symptoms are present for at least 3 days per month over a 3-month period. Although people with IBS-C report suffering from many of the same symptoms associated with constipation, the presence of abdominal discomfort and pain is what differentiates IBS-C from chronic constipation. Additionally, the hypersensitivity of the gastrointestinal system of individuals with IBS makes them more prone to experience the effects of even mild symptoms of constipation or diarrhea. The condition is approximately 2 to 2.5 times more prevalent in women than men, and women are more likely to report a history of constipation.

About AMITIZA(R) (lubiprostone) 24 mcg BID for Chronic Idiopathic Constipation

AMITIZA is indicated for the treatment of Chronic Idiopathic Constipation in the adult population. AMITIZA should not be used in patients with a known hypersensitivity to any components of the formulation and in patients with a history of mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be evaluated prior to initiating AMITIZA treatment.

The safety of AMITIZA in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.

AMITIZA should not be administered to patients that have severe diarrhea. Patients should be aware
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Aug. 17, 2011 Reportlinker.com announces that ... in its catalogue: Levosimendan ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary ... patent information. Pipeline Developer is ...
... 16, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with ... The Journal of the American Medical Association ( ... resulted in significant and sustained reductions in uric acid ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:7/11/2014)... Williamsburg, VA (PRWEB) July 11, 2014 Riverside ... Continuing Care (CBCC) in Virginia in late 2012 and ... – ChooseHome – to residents throughout the Williamsburg and Newport ... CBCC programs provide services and benefits to independent older adults ... have access to a safety net of continuing care services ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Last ... their staff. Jim Siddons joins the agency as a ... graduated in 1994 with a Bachelor’s Degree in Business ... of industry experience and will manage everything from performance ... for trucking to the specialized needs for those in ...
(Date:7/11/2014)... Europe is one of the largest consumers ... irrigated land area. The agricultural sector is a significant ... 30.0% of the total water use. The scale and ... region, but far from negligible in most northern ones. ... 60.0% of the water use in most countries, while ...
(Date:7/11/2014)... The “Proteomics Market by Technology (Protein Microarray, ... Resonance, X-ray Crystallography) - Instruments, Reagents & Services ... the major market drivers, restraints, and opportunities in ... the World (RoW). , The proteomics market has ... mainly due to the increasing need of proteomic ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually ... namely protective coating, opacity, and coloring. These are water ... color to substances such as paper, paints, plastics, and ... upon application impart color to the substance. Some examples ... and hematite. , The coloring action of pigments is ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3
... HARRISBURG, Pa., Jan. 3 Consumers who,purchased or ... from,the Schumacher,s Inn in Austin, Potter County, should ... Botulism contamination, Health Secretary Dr. Calvin B.,Johnson said ... the restaurant should,immediately contact the Pennsylvania Department of ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer ... a registration,statement covering the resale of 53,747,555 shares ... and Exchange Commission on January,2, 2008., This ... does not,represent a solicitation or offer to buy ...
... mind can affect the body,s health, researchers say , , THURSDAY, ... say they have prescribed a placebo to a patient during ... A majority of doctors in the study also said they ... accept a mind-body relationship that can affect health, the ...
... faster cancer growth and earlier death, agency says ... studies offer further evidence of the health risks posed ... U.S. officials announced Thursday. , The studies showed that ... the drugs as treatment for chemotherapy-induced anemia died sooner ...
... treated for hypothyroidism aren,t likely to drop pounds with ... the Journal of Pediatrics. The study is the first ... loss in pediatric patients., Parents of overweight children ... request thyroid tests, but, unfortunately, screening for hypothyroidism is ...
... with radiation, finding no raised risk to heart , , ... that a common but controversial treatment for prostate cancer ... of heart problems, as some specialists had feared. ... a combination of testosterone-lowering drugs and radiation therapy appeared ...
Cached Medicine News:Health News:Health Department Warns Consumers of Home-Canned Soup Linked to Potter County Restaurant 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Almost Half of Doctors Have Prescribed Placebos 2Health News:FDA Reports New Risks Posed by Anemia Drugs 2Health News:FDA Reports New Risks Posed by Anemia Drugs 3Health News:Thyroid treatment no 'quick fix' for weight loss in children 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: